miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease.

Autor: Dos Santos MCT; Experimental Medicine and Diagnostics, Global Exploratory Development, UCB Biopharma SPRL, Braine-l'Alleud, Belgium., Barreto-Sanz MA; SimplicityBio SA, Monthey, Switzerland., Correia BRS; Hospital Sirio Libanes, São Paulo, Brazil., Bell R; Centre for Misfolding Diseases, University of Cambridge, Cambridge, UK., Widnall C; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK., Perez LT; Bioanalytical Sciences, Non Clinical Development, UCB Biopharma SPRL, Belgium., Berteau C; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK., Schulte C; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen and German Center for Neurodegenerative Diseases, Tuebingen, Germany., Scheller D; Consultancy Neuropharm, Neukirchener, Neuss, Germany., Berg D; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen and German Center for Neurodegenerative Diseases, Tuebingen, Germany.; Department of Neurology, Christian-Albrechts-University Kiel, Kiel, Germany., Maetzler W; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen and German Center for Neurodegenerative Diseases, Tuebingen, Germany.; Department of Neurology, Christian-Albrechts-University Kiel, Kiel, Germany., Galante PAF; Hospital Sirio Libanes, São Paulo, Brazil., Nogueira da Costa A; Experimental Medicine and Diagnostics, Global Exploratory Development, UCB Biopharma SPRL, Braine-l'Alleud, Belgium.

Publikováno v: Oncotarget [Oncotarget] 2018 Apr 03; Vol. 9 (25), pp. 17455-17465. Date of Electronic Publication: 2018 Apr 03 (Print Publication: 2018).